Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
b-cell activating factor receptor chimeric antigen receptor t-cell
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
B-cell activating factor receptor (BAFF-R) chimeric antigen receptor (CAR) T-cell therapy is an autologous cellular immunotherapy designed to target malignant B cells. Developed by the Mayo Clinic, the specific candidate MC10029 utilizes a patient's own T cells genetically engineered to express a CAR targeting BAFF-R, a receptor critical for B-cell survival and consistently expressed on various B-cell malignancies. This approach is particularly relevant for patients with relapsed or refractory disease, including those who have developed resistance to CD19-targeted therapies or exhibit CD19-negative tumor escape. The therapy is currently being evaluated in Phase 1 clinical trials for B-cell hematologic malignancies such as chronic lymphocytic leukemia (CLL).
- Other names
- B-cell activating factor receptor chimeric antigen receptor T-cellBAFFR CAR-T
02
Targets
TNFRSF13C (B-cell Activating Factor Receptor)
Beyond the preview
Go deeper on b-cell activating factor receptor chimeric antigen receptor t-cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on b-cell activating factor receptor chimeric antigen receptor t-cell.